Perhaps nothing defines today's pharmaceutical industry as accurately as the "patent cliff." The expiration of the patents of numerous high-selling, high-profile drugs has dominated the industry like ...
Pfizer’s broad pipeline and recent acquisitions have yet to translate into a coherent market narrative, contributing to investor uncertainty during a critical period of strategic transition. Few ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results